MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer
Metrics: PDF 938 views | HTML 1265 views | ?
Evert van den Broek1,5, Sjoerd H. den Uil1,2, Veerle M.H. Coupé3, Pien M. Delis-van Diemen1,5, Anne S. Bolijn1,5, Herman Bril4, Hein B.A.C. Stockmann2, Nicole C.T. van Grieken1, Gerrit A. Meijer1,5 and Remond J.A. Fijneman1,5
1Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
2Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands
3Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands
4Department of Pathology, Spaarne Gasthuis, Haarlem, The Netherlands
5Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Remond J.A. Fijneman, email: R.Fijneman@nki.nl
Keywords: colon cancer; disease recurrence; predictive biomarker; MACROD2; response to chemotherapy
Received: May 10, 2017 Accepted: June 01, 2018 Published: June 29, 2018
Background: Colorectal cancer (CRC) is caused by genetic aberrations. MACROD2 is commonly involved in somatic focal DNA copy number losses, in more than one-third of CRCs. In this study, we aimed to investigate the association of MACROD2 protein expression with clinical outcome in stage II and stage III colon cancer.
Methods: Tissue microarrays (TMA) containing formalin-fixed paraffin-embedded tissue cores from 386 clinically well-annotated primary stage II and III colon cancers were stained by immunohistochemistry and evaluated for MACROD2 protein expression. Disease-free survival (DFS) analysis was performed to estimate association with clinical outcome.
Results: Loss of nuclear MACROD2 protein expression in epithelial neoplastic cells of stage III microsatellite stable (MSS) colon cancers was associated with poor DFS within the subgroup of 59 patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy (p=0.005; HR=3.8, 95% CI 1.4-10.0).
Conclusion: These data indicate that low nuclear expression of MACROD2 is associated with poor prognosis of patients with stage III MSS primary colon cancer who were treated with 5-FU-based adjuvant chemotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.